TYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tyra Biosciences Inc (TYRA) presents a compelling long-term investment opportunity for a beginner investor with $50,000-$100,000 available. Despite a slight pre-market dip, the stock has strong analyst support, significant upside potential due to its FGFR3 inhibitor pipeline, and a robust cash position to fund operations into 2027. The technical indicators and options data suggest a neutral to slightly bullish sentiment, making this a good buy for long-term growth.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. The MACD histogram is negative but contracting, suggesting potential stabilization. RSI is neutral at 67.976, and the stock is trading near its resistance level of 38.754, with support at 36.787. Overall, the technical indicators lean slightly bullish.
Strong analyst support with multiple Overweight/Outperform ratings and price targets raised to as high as $59.
Boone Capital Management's recent acquisition of 398,482 shares reflects institutional confidence.
The company's focus on three high-value Phase 2 clinical programs targeting FGFR3 biology, with significant market potential in oncology and growth disorders.
Robust cash position of $256 million to fund operations into 2027.
The company reported a net loss of $120 million over the past year, though this is typical for biotech firms in the development phase.
The stock has already increased 47% since last quarter, which might limit short-term upside.
In Q4 2025, the company reported a net income loss of -$33.83 million, improving by 32.31% YoY. EPS also improved by 32.56% YoY to -0.57. While revenue remains at $0, the company is in a development phase with a strong cash position of $256 million to fund operations into 2027.
Analysts are highly bullish on TYRA, with multiple firms raising price targets and initiating Overweight/Outperform ratings. The highest price target is $59.62, reflecting significant upside potential from the current price of $37.6. Analysts highlight the company's FGFR3 inhibitor pipeline as a key growth driver, with blockbuster potential in oncology and growth disorders.
